DE3034975C2 - Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen - Google Patents
Arzneimittelkombination zur Behandlung infektiöser AtemwegerkrankungenInfo
- Publication number
- DE3034975C2 DE3034975C2 DE3034975A DE3034975A DE3034975C2 DE 3034975 C2 DE3034975 C2 DE 3034975C2 DE 3034975 A DE3034975 A DE 3034975A DE 3034975 A DE3034975 A DE 3034975A DE 3034975 C2 DE3034975 C2 DE 3034975C2
- Authority
- DE
- Germany
- Prior art keywords
- ambroxol
- amino
- antibiotic
- erythromycin
- ampicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000890 drug combination Substances 0.000 title claims description 3
- 208000023504 respiratory system disease Diseases 0.000 title claims 4
- 208000015181 infectious disease Diseases 0.000 title claims 3
- 230000002458 infectious effect Effects 0.000 title claims 3
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 45
- 229960005174 ambroxol Drugs 0.000 claims description 40
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 37
- 229940106164 cephalexin Drugs 0.000 claims description 14
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 14
- 229960003276 erythromycin Drugs 0.000 claims description 14
- 229960003022 amoxicillin Drugs 0.000 claims description 11
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 11
- 229960000723 ampicillin Drugs 0.000 claims description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 11
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 229960003722 doxycycline Drugs 0.000 claims description 9
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- JBDGDEWWOUBZPM-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]-1-cyclohexanol Chemical compound NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 JBDGDEWWOUBZPM-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 241000700157 Rattus norvegicus Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960005091 chloramphenicol Drugs 0.000 claims 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000008187 granular material Substances 0.000 description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 239000013530 defoamer Substances 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 229960002216 methylparaben Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LMULSOUAONYGOV-UHFFFAOYSA-K C(CC)OC(=O)C1=CC=C(O)C=C1.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] Chemical class C(CC)OC(=O)C1=CC=C(O)C=C1.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] LMULSOUAONYGOV-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940043684 ambroxol / ampicillin Drugs 0.000 description 1
- 229940025360 ambroxol / cephalexin Drugs 0.000 description 1
- 229940010026 ambroxol / doxycycline Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3034975A DE3034975C2 (de) | 1980-09-17 | 1980-09-17 | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen |
| CH5962/81A CH648209A5 (de) | 1980-09-17 | 1981-09-15 | Arzneimittelkombination zur behandlung infektioeser atemwegserkrankungen. |
| ZA816417A ZA816417B (en) | 1980-09-17 | 1981-09-16 | Pharmaceutical composition,especially for treating infectious diseases of the respiratory tract |
| GB8127983A GB2083749B (en) | 1980-09-17 | 1981-09-16 | Drug combination comprising ambroxol and an antibiotic for the treatment of infectious diseases of the respiratory tract |
| IE2147/81A IE51517B1 (en) | 1980-09-17 | 1981-09-16 | Drug combination for the treatment of infectious diseases of the respiratory tract |
| FR8117603A FR2493145A1 (fr) | 1980-09-17 | 1981-09-17 | Combinaison medicamenteuse pour le traitement des maladies infectieuses des voies respiratoires |
| SG7/85A SG785G (en) | 1980-09-17 | 1985-01-04 | Drug combination for the treatment of infectious diseases of the respiratory tract |
| HK207/85A HK20785A (en) | 1980-09-17 | 1985-03-21 | Drug combination for the treatment of infectious diseases of the respiratory tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3034975A DE3034975C2 (de) | 1980-09-17 | 1980-09-17 | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3034975A1 DE3034975A1 (de) | 1982-04-29 |
| DE3034975C2 true DE3034975C2 (de) | 1986-11-27 |
Family
ID=6112126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3034975A Expired DE3034975C2 (de) | 1980-09-17 | 1980-09-17 | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| CH (1) | CH648209A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE3034975C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2493145A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2083749B (cg-RX-API-DMAC7.html) |
| HK (1) | HK20785A (cg-RX-API-DMAC7.html) |
| IE (1) | IE51517B1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG785G (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA816417B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5888311A (ja) * | 1981-11-20 | 1983-05-26 | Teijin Ltd | 呼吸器疾患治療剤 |
| AUPN115095A0 (en) * | 1995-02-15 | 1995-03-09 | Butt, Henry Lawrence | Analysis of and compositions and methods for the treatment of disease |
| DE19933148A1 (de) * | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| DE10208313A1 (de) * | 2002-02-27 | 2003-09-11 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
| US20030166732A1 (en) * | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| CN1323662C (zh) * | 2004-06-18 | 2007-07-04 | 江苏恒瑞医药股份有限公司 | 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用 |
| CN100434078C (zh) * | 2005-05-16 | 2008-11-19 | 天津药物研究院 | 一种盐酸氨溴索复方缓释片及其制备方法 |
| RU2749902C2 (ru) * | 2018-10-31 | 2021-06-18 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795585A (fr) * | 1972-02-17 | 1973-08-16 | Thomae Gmbh Dr K | Nouveau medicament pulmonaire |
-
1980
- 1980-09-17 DE DE3034975A patent/DE3034975C2/de not_active Expired
-
1981
- 1981-09-15 CH CH5962/81A patent/CH648209A5/de not_active IP Right Cessation
- 1981-09-16 ZA ZA816417A patent/ZA816417B/xx unknown
- 1981-09-16 IE IE2147/81A patent/IE51517B1/en not_active IP Right Cessation
- 1981-09-16 GB GB8127983A patent/GB2083749B/en not_active Expired
- 1981-09-17 FR FR8117603A patent/FR2493145A1/fr active Granted
-
1985
- 1985-01-04 SG SG7/85A patent/SG785G/en unknown
- 1985-03-21 HK HK207/85A patent/HK20785A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2493145B1 (cg-RX-API-DMAC7.html) | 1984-12-21 |
| GB2083749A (en) | 1982-03-31 |
| CH648209A5 (de) | 1985-03-15 |
| IE51517B1 (en) | 1987-01-07 |
| DE3034975A1 (de) | 1982-04-29 |
| FR2493145A1 (fr) | 1982-05-07 |
| ZA816417B (en) | 1983-05-25 |
| IE812147L (en) | 1982-03-17 |
| SG785G (en) | 1985-06-14 |
| HK20785A (en) | 1985-03-29 |
| GB2083749B (en) | 1984-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69910186T2 (de) | Pharmazeutische zusammensetzung von topiramate | |
| DE69924381T2 (de) | Leicht zerfallende feste zubereitung | |
| DE69315257T2 (de) | Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen | |
| DE2636152C2 (de) | Verfahren zur Herstellung von Dragees | |
| DE69727000T2 (de) | Arzneimittel mit verzögerter Wirkstoffabgabe enthaltend Venlafaxin | |
| EP1207868B1 (de) | Pharmazeutische tramadolsalze | |
| EP1067905B1 (de) | Brauseformulierungen | |
| EP1165081B1 (de) | Verfahren zum herstellen tolperison-enthaltender pharmazeutischer zubereitungen zur oralen verabreichung | |
| DE69813602T2 (de) | Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe | |
| DD285720A5 (de) | Verfahren zur herstellung einer saeurebindenden, aufschaeumenden zubereitung | |
| EP0339420B1 (de) | DHP-Retard-Zubereitung | |
| DE60006362T2 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
| DE3034975C2 (de) | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen | |
| EP0471388B1 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
| EP0301373B1 (de) | Erzeugnisse, enthaltend Gallopamil und Prazosin | |
| EP1038526A1 (de) | Behandlung von funktionellen Störungen der unteren Darmwege und einhergehenden visceralen Schmerzen mit Moxonidin | |
| DE2207460C2 (de) | Verwendung von Hydroxycylohexylaminderivaten bei der Behandlung von ödematös atelektatischen Lungenveränderungen | |
| DE3432411A1 (de) | Antiadhaesive prohylactica und arzneimittel, enthaltend ein sekretolytisch wirksames benzylaminderivat | |
| DE3535950A1 (de) | Kombinationspraeparat | |
| EP3235492B1 (de) | Verwendung von homoeriodictyol (hed) zum reduzieren der magensäuresekretions-stimulierenden wirkung von n-acetyl-4-aminophenol (paracetamol) | |
| EP0192098B1 (de) | Verwendung des 2-Amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepins zur Herstellung eines zur Behandlung der Parkinsonschen Erkrankung bzw. des Parkinsonismus geeigneten Arzneimittels | |
| DE202019005745U1 (de) | Schmelztabletten umfassend Glycopyrrolat mit erhöhter Bioverfügbarkeit | |
| EP0418553A1 (de) | Hochwirksame, schnell resorbierbare Zubereitungsformen von Glibenclamid, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2256538C2 (de) | Probenecidsalz des Pivaloyloxymethylesters von D-(-)-α-Aminobenzylpenicillin, seine Herstellung und diese enthaltende pharmazeutische Mittel | |
| EP0557670A1 (de) | Minocyclin enthaltende Pellets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |